Shots:
- Apogee has reported maintenance data from Part A of the P-II (APEX) trial assessing zumilokibart (APG777; 360mg at Q3M or Q6M) in pts with mod. to sev. atopic dermatitis
- Trial showed 75% (Q3M) & 85% (Q6M) of Wk. 16 zumilokibart-responders maintained EASI-75, while 86% (Q3M) & 78% (Q6M) sustained vIGA 0/1, with continued deepening of response across all lesions & itch endpoints; data were presented at AAD’26
- APEX Part B is assessing high, medium, or low-dose zumilokibart vs PBO in 347 pts, with 16wk. data expected in the Q2’26, while the company is planning to begin P-III trial in the H2’26, enabling a potential launch in 2029
Ref: Apogee | Image: Apogee | Press Release
Related News: Apogee Therapeutics Reports P-II (APEX) Trial Data on APG777 for Atopic Dermatitis (AD)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
